SAB Biotherapeutics (SABS) Gains from Investment Securities (2020 - 2026)
SAB Biotherapeutics (SABS) reported Gains from Investment Securities of $37388.0 for Q1 2026, up 8.0% on a YoY basis from $34618.0 in Q1 2025, and down 98.39% quarter-over-quarter from $2.3 million in Q4 2025.
SAB Biotherapeutics (SABS) Gains from Investment Securities (2020 - 2026) Analysis & Trends
SAB Biotherapeutics has reported Gains from Investment Securities for 7 years, with the latest figure at $37388.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities rose 8.0% year-over-year to $37388.0; the trailing twelve-month figure through Mar 2026 stood at -$58.6 million (down 2491.84% YoY), and the FY2025 full-year result was $20.9 million, up 603.78% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $37388.0, down from $2.3 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $9.6 million in Q1 2023, with the low at -$61.6 million in Q3 2025.
- Historically, Gains from Investment Securities has averaged -$4.0 million across 5 years, with a median of $29665.5 in 2022.
- Annual changes were most pronounced in 2023 — Gains from Investment Securities soared 38732.45% — and 2025, when it sank 998099.77%.
- SAB Biotherapeutics' Gains from Investment Securities stood at -$10.4 million in 2022, then soared by 146.15% to $4.8 million in 2023, then sank by 101.52% to -$73114.0 in 2024, then surged by 3268.07% to $2.3 million in 2025, then slumped by 98.39% to $37388.0 in 2026.
- The last three Gains from Investment Securities figures came in at $37388.0 (Q1 2026), $2.3 million (Q4 2025), and -$61.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | SAB Biotherapeutics | 214.77 Mn | 214.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37,388.00 |
| Mar 31, 2026 | 37,388.00 |
| Dec 31, 2025 | 2.32 Mn |
| Dec 31, 2025 | 2.32 Mn |
| Sep 30, 2025 | -61.60 Mn |
| Sep 30, 2025 | -61.60 Mn |
| Jun 30, 2025 | 627,056.00 |
| Jun 30, 2025 | 627,056.00 |
| Mar 31, 2025 | 34,618.00 |
| Mar 31, 2025 | 34,618.00 |
| Dec 31, 2024 | -73,114.00 |
| Dec 31, 2024 | -73,114.00 |
| Sep 30, 2024 | -6,171.00 |
| Sep 30, 2024 | -6,171.00 |
| Jun 30, 2024 | -2.22 Mn |
| Jun 30, 2024 | -2.22 Mn |
| Mar 31, 2024 | -5.47 Mn |
| Mar 31, 2024 | -5.47 Mn |
| Dec 31, 2023 | 4.81 Mn |
| Dec 31, 2023 | 4.81 Mn |